Navigation Links
PRT versus IMRT toxicity in Medicare beneficiaries with prostate cancer
Date:12/17/2012

There is no difference between proton radiotherapy (PRT) and intensity-modulated radiotherapy (IMRT) when comparing the toxicity among Medicare beneficiary patients with prostate cancer at 12 months post-treatment according to a study published December 14 in the Journal of the National Cancer Institute.

IMRT is the standard form of radiotherapy for the treatment of prostate cancer, accounting for more than 80% of all treatments. Alternative treatments for radiotherapy have emerged, with the most notable being PRT. PRT treatment has surfaced partly due Medicare reimbursement, which reimburses PRT at a rate of 1.4-2.5 times that of IMRT. Despite its widespread use, the benefits and harms of PRT compared with other types of radiotherapy remain unknown.

To determine the long-term effects of PRT treatment compared with IMRT treatment, James B. Yu, M.D., Yale University School of Medicine, Department of Therapeutic Radiology, and colleagues performed a retrospective study of all Medicare beneficiaries aged 66 years or older who had received PRT or IMRT for prostate cancer during 2008 and/or 2009. Each PRT patient was then matched with two IMRT patients with both similar clinical and sociodemographic characteristics to assess the toxicity of each treatment, while the cost of IMRT or PRT treatment was calculated for each patient using the sum of Medicare reimbursements for outpatient and physician claims.

The researchers found that patients who received PRT were younger, healthier and from more thriving areas than those who received IMRT. While PRT was linked to a statistically significant reduction in genitourinary toxicity at 6 months compared with IMRT, there was no statistically significant difference in gastrointestinal or other toxicities at 6 or 12 months post-treatment. "The relative reimbursement of new medical technologies needs to be considered carefully so that physicians and hospitals do not have a financial incentive to adopt a technology before supporting evidence is available," the researchers write. "Continued longitudinal study of the comparative effectiveness of PRT compared with IMRT is needed before widespread application of PRT for prostate cancer can be justified."

In an accompanying editorial, Justin E. Bekelman, M.D., Abramson Cancer Center, Perelman Center for Advanced Medicine and Stephen M. Hahn, M.D., Chair and Henry K. Pancoast Professor of Radiation Oncology at the University of Pennsylvania School of Medicine, write that the study has limitations and could lead to misclassifications of the results. "Without studies to validate the surrogacy of claims-based endpoints, outcome misclassification could lead to false-negative or false-positive results," they write.

In another accompanying editorial, Theodore S. Lawrence, M.D., Ph.D., Chair, Radiation Oncology, University of Michigan, and Mary Feng, M.D., Department of Radiation Oncology, University of Michigan, write that, "It is assumed that one can assess toxicity by evaluating billing codes, but toxicities are not well graded, and many could be missed," arguing that a thorough comparison of the two treatments cannot yet be made. "Although it seems unlikely that proton therapy will be superior to IMRT photons for prostate cancer, protons may be superior for tumors in which the elimination of the low-dose regions might decrease normal tissue injury (eg, lung cancers, when combined with chemotherapy)."


'/>"/>
Contact: Zachary Rathner
Zachary.Rathner@oup.com
301-841-1286
Journal of the National Cancer Institute
Source:Eurekalert

Related medicine news :

1. New genetic clues to why most bone marrow transplant patients develop graft-versus-host disease
2. New Polar RCX3 Heart Rate Monitor Versus Suunto Quest
3. Studies assess genetics, modified treatment to improve outcomes, reduce toxicity
4. First-of-its-kind approach nanomedicine design effectively targets cancer with decreased toxicity
5. Study suggests eliminating Medicare consultation payments associated with a net increase in spending
6. Costly, Repeat Medical Testing Common for Medicare Patients: Study
7. Study suggests repeat testing common among medicare beneficiaries
8. Medicare: Barrier to hospice increases hospitalization
9. Canadas health costs for seniors rising slowly: Points way to Medicare solvency
10. Medicare Gaps Leave Many With Big Bill at End of Life, Study Finds
11. Health-care costs at end of life exceed total assets for 25 percent of Medicare population
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... ... announces the Gyrociser, an exercise invention which aids in proper muscle development. , ... Cooper, CEO and Creative Director of World Patent Marketing. "Globalization has threatened the ...
(Date:4/29/2016)... ... ... type of skin cancer. Although only about 1 percent of skin cancer cases are melanoma, ... are expected to die of melanoma this year. The risk increases with age, and while ... diagnosed cancers in young women. A recent breakthrough in genetic studies may give doctors the ...
(Date:4/29/2016)... NY (PRWEB) , ... April 29, 2016 , ... New York City based oral and ... This surgery is a very effective way to treat obstructive sleep apnea. Dr. Jamali is ... Orthognathic surgery is a procedure that involves one or both jaw bones. This surgery is ...
(Date:4/29/2016)... ... April 29, 2016 , ... For those who skip meals occasionally (which is ... was among the many new lifestyle diet tips offered by nutritionists Pam Bonney and ... of Water® radio show. Bonny and Lawrence noted that because proper nutrition, including water, ...
(Date:4/29/2016)... FL (PRWEB) , ... April 29, 2016 , ... ... will feature Grassland Dairy Products, Inc. in an upcoming episode, airing third quarter ... a century of churning cream into butter, Grassland Dairy Products, located in Greenwood, ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... , April 27, 2016  Bayer Animal Health ... senior from the University of Florida College of ... Bayer Excellence in Communication Award (BECA). Brittany was ... were awarded a total of $70,000 in scholarship ... four years, Bayer has provided a total of ...
(Date:4/27/2016)... NEW YORK , April 27, 2016 /PRNewswire/ ... OASM ), a developer of a new ... today announced positive overall survival results for Paclical/Apealea ... total of 789 patients with epithelial ovarian cancer. ... treatment groups: Paclical/Apealea in combination with carboplatin versus ...
(Date:4/27/2016)... 27, 2016 At the Sachs ... of a Phase 2 clinical study of its lead ... undergoing cochlear implantation (CI) surgery. This large, placebo-controlled, double-blind, ... Germany and France ... at the time of surgery. "Despite advances in cochlear ...
Breaking Medicine Technology: